nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—Tamoxifen—breast cancer	0.354	1	CrCtD
Cyclobenzaprine—CYP2D6—breast cancer	0.075	0.538	CbGaD
Cyclobenzaprine—CYP3A4—breast cancer	0.0644	0.462	CbGaD
Cyclobenzaprine—Naftifine—Toremifene—breast cancer	0.028	0.117	CrCrCtD
Cyclobenzaprine—Tamoxifen—Toremifene—breast cancer	0.0232	0.0973	CrCrCtD
Cyclobenzaprine—Doxylamine—Toremifene—breast cancer	0.0194	0.0814	CrCrCtD
Cyclobenzaprine—CYP1A2—Anastrozole—breast cancer	0.0191	0.109	CbGbCtD
Cyclobenzaprine—Naftifine—Tamoxifen—breast cancer	0.0176	0.0737	CrCrCtD
Cyclobenzaprine—CYP1A2—Toremifene—breast cancer	0.0175	0.0993	CbGbCtD
Cyclobenzaprine—Bromodiphenhydramine—Toremifene—breast cancer	0.0164	0.0688	CrCrCtD
Cyclobenzaprine—Clofedanol—Toremifene—breast cancer	0.0133	0.0559	CrCrCtD
Cyclobenzaprine—CYP3A4—Exemestane—breast cancer	0.0132	0.0751	CbGbCtD
Cyclobenzaprine—Benzphetamine—Toremifene—breast cancer	0.0129	0.0541	CrCrCtD
Cyclobenzaprine—Orphenadrine—Toremifene—breast cancer	0.0129	0.0541	CrCrCtD
Cyclobenzaprine—Doxylamine—Tamoxifen—breast cancer	0.0122	0.0511	CrCrCtD
Cyclobenzaprine—CYP2D6—Idarubicin—breast cancer	0.0119	0.0678	CbGbCtD
Cyclobenzaprine—Diphenhydramine—Toremifene—breast cancer	0.0115	0.048	CrCrCtD
Cyclobenzaprine—CYP3A4—Letrozole—breast cancer	0.0112	0.0638	CbGbCtD
Cyclobenzaprine—Tripelennamine—Tamoxifen—breast cancer	0.011	0.0463	CrCrCtD
Cyclobenzaprine—Bromodiphenhydramine—Tamoxifen—breast cancer	0.0103	0.0432	CrCrCtD
Cyclobenzaprine—Dimetacrine—Tamoxifen—breast cancer	0.0103	0.0432	CrCrCtD
Cyclobenzaprine—CYP3A4—Anastrozole—breast cancer	0.01	0.0569	CbGbCtD
Cyclobenzaprine—CYP3A4—Toremifene—breast cancer	0.00915	0.052	CbGbCtD
Cyclobenzaprine—CYP3A4—Fulvestrant—breast cancer	0.00851	0.0484	CbGbCtD
Cyclobenzaprine—Clofedanol—Tamoxifen—breast cancer	0.00837	0.0351	CrCrCtD
Cyclobenzaprine—Benzphetamine—Tamoxifen—breast cancer	0.0081	0.034	CrCrCtD
Cyclobenzaprine—Orphenadrine—Tamoxifen—breast cancer	0.0081	0.034	CrCrCtD
Cyclobenzaprine—Promazine—Tamoxifen—breast cancer	0.00773	0.0324	CrCrCtD
Cyclobenzaprine—CYP3A4—Thiotepa—breast cancer	0.00758	0.0431	CbGbCtD
Cyclobenzaprine—Diphenhydramine—Tamoxifen—breast cancer	0.00719	0.0302	CrCrCtD
Cyclobenzaprine—CYP3A4—Ixabepilone—breast cancer	0.00694	0.0394	CbGbCtD
Cyclobenzaprine—CYP3A4—Lapatinib—breast cancer	0.00668	0.038	CbGbCtD
Cyclobenzaprine—CYP1A2—Tamoxifen—breast cancer	0.00638	0.0363	CbGbCtD
Cyclobenzaprine—CYP2D6—Vinorelbine—breast cancer	0.00583	0.0331	CbGbCtD
Cyclobenzaprine—CYP2D6—Tamoxifen—breast cancer	0.00526	0.0299	CbGbCtD
Cyclobenzaprine—CYP3A4—Raloxifene—breast cancer	0.00506	0.0288	CbGbCtD
Cyclobenzaprine—CYP1A2—Fluorouracil—breast cancer	0.0047	0.0267	CbGbCtD
Cyclobenzaprine—CYP3A4—Vinorelbine—breast cancer	0.0037	0.0211	CbGbCtD
Cyclobenzaprine—CYP2D6—Vinblastine—breast cancer	0.00359	0.0204	CbGbCtD
Cyclobenzaprine—CYP3A4—Tamoxifen—breast cancer	0.00334	0.019	CbGbCtD
Cyclobenzaprine—CYP3A4—Mitoxantrone—breast cancer	0.00326	0.0185	CbGbCtD
Cyclobenzaprine—CYP3A4—Paclitaxel—breast cancer	0.0026	0.0148	CbGbCtD
Cyclobenzaprine—CYP3A4—Irinotecan—breast cancer	0.00257	0.0146	CbGbCtD
Cyclobenzaprine—CYP3A4—Vinblastine—breast cancer	0.00228	0.013	CbGbCtD
Cyclobenzaprine—CYP2D6—Doxorubicin—breast cancer	0.00221	0.0125	CbGbCtD
Cyclobenzaprine—CYP3A4—Docetaxel—breast cancer	0.00188	0.0107	CbGbCtD
Cyclobenzaprine—CYP3A4—Doxorubicin—breast cancer	0.0014	0.00797	CbGbCtD
Cyclobenzaprine—Tamoxifen—ESRRA—breast cancer	0.000229	0.148	CrCbGaD
Cyclobenzaprine—Dimetacrine—ACHE—breast cancer	0.000184	0.119	CrCbGaD
Cyclobenzaprine—Tamoxifen—SULT1A1—breast cancer	0.000174	0.112	CrCbGaD
Cyclobenzaprine—Orphenadrine—SCN10A—breast cancer	5.66e-05	0.0366	CrCbGaD
Cyclobenzaprine—Protriptyline—CYP2D6—breast cancer	5.19e-05	0.0336	CrCbGaD
Cyclobenzaprine—Tamoxifen—ESR2—breast cancer	4.89e-05	0.0316	CrCbGaD
Cyclobenzaprine—Tripelennamine—CYP2D6—breast cancer	4.66e-05	0.0302	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP1B1—breast cancer	4.46e-05	0.0288	CrCbGaD
Cyclobenzaprine—Olopatadine—CYP3A4—breast cancer	3.95e-05	0.0256	CrCbGaD
Cyclobenzaprine—Protriptyline—ABCB1—breast cancer	3.71e-05	0.024	CrCbGaD
Cyclobenzaprine—Alimemazine—CYP3A4—breast cancer	3.61e-05	0.0233	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP19A1—breast cancer	3.27e-05	0.0212	CrCbGaD
Cyclobenzaprine—Tamoxifen—ABCG2—breast cancer	3.07e-05	0.0199	CrCbGaD
Cyclobenzaprine—Tamoxifen—ESR1—breast cancer	3.01e-05	0.0195	CrCbGaD
Cyclobenzaprine—Nortriptyline—PTGS1—breast cancer	2.92e-05	0.0189	CrCbGaD
Cyclobenzaprine—Diphenhydramine—PTGS1—breast cancer	2.7e-05	0.0175	CrCbGaD
Cyclobenzaprine—Tamoxifen—CYP1A1—breast cancer	2.41e-05	0.0156	CrCbGaD
Cyclobenzaprine—Gastrointestinal pain—Paclitaxel—breast cancer	2.32e-05	0.00033	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Gemcitabine—breast cancer	2.32e-05	0.00033	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Doxorubicin—breast cancer	2.31e-05	0.000328	CcSEcCtD
Cyclobenzaprine—Dizziness—Irinotecan—breast cancer	2.3e-05	0.000327	CcSEcCtD
Cyclobenzaprine—Stomatitis—Doxorubicin—breast cancer	2.3e-05	0.000326	CcSEcCtD
Cyclobenzaprine—Jaundice—Doxorubicin—breast cancer	2.3e-05	0.000326	CcSEcCtD
Cyclobenzaprine—Anorexia—Docetaxel—breast cancer	2.29e-05	0.000326	CcSEcCtD
Cyclobenzaprine—Shock—Capecitabine—breast cancer	2.29e-05	0.000326	CcSEcCtD
Cyclobenzaprine—Hepatitis—Epirubicin—breast cancer	2.28e-05	0.000325	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Fluorouracil—breast cancer	2.28e-05	0.000324	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Capecitabine—breast cancer	2.28e-05	0.000324	CcSEcCtD
Cyclobenzaprine—Tinnitus—Methotrexate—breast cancer	2.28e-05	0.000323	CcSEcCtD
Cyclobenzaprine—Tachycardia—Capecitabine—breast cancer	2.27e-05	0.000323	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Epirubicin—breast cancer	2.27e-05	0.000323	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Epirubicin—breast cancer	2.27e-05	0.000322	CcSEcCtD
Cyclobenzaprine—Sweating—Doxorubicin—breast cancer	2.26e-05	0.000321	CcSEcCtD
Cyclobenzaprine—Urticaria—Paclitaxel—breast cancer	2.26e-05	0.00032	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Capecitabine—breast cancer	2.25e-05	0.00032	CcSEcCtD
Cyclobenzaprine—Hypotension—Docetaxel—breast cancer	2.25e-05	0.000319	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Paclitaxel—breast cancer	2.24e-05	0.000319	CcSEcCtD
Cyclobenzaprine—Anorexia—Capecitabine—breast cancer	2.22e-05	0.000315	CcSEcCtD
Cyclobenzaprine—Vomiting—Mitoxantrone—breast cancer	2.21e-05	0.000314	CcSEcCtD
Cyclobenzaprine—Vomiting—Irinotecan—breast cancer	2.21e-05	0.000314	CcSEcCtD
Cyclobenzaprine—Dizziness—Fluorouracil—breast cancer	2.2e-05	0.000313	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Doxorubicin—breast cancer	2.2e-05	0.000312	CcSEcCtD
Cyclobenzaprine—Rash—Irinotecan—breast cancer	2.19e-05	0.000312	CcSEcCtD
Cyclobenzaprine—Rash—Mitoxantrone—breast cancer	2.19e-05	0.000312	CcSEcCtD
Cyclobenzaprine—Dermatitis—Irinotecan—breast cancer	2.19e-05	0.000312	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mitoxantrone—breast cancer	2.19e-05	0.000312	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Docetaxel—breast cancer	2.19e-05	0.000311	CcSEcCtD
Cyclobenzaprine—Headache—Mitoxantrone—breast cancer	2.18e-05	0.00031	CcSEcCtD
Cyclobenzaprine—Headache—Irinotecan—breast cancer	2.18e-05	0.00031	CcSEcCtD
Cyclobenzaprine—Hypotension—Capecitabine—breast cancer	2.18e-05	0.000309	CcSEcCtD
Cyclobenzaprine—Insomnia—Docetaxel—breast cancer	2.18e-05	0.000309	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Docetaxel—breast cancer	2.16e-05	0.000307	CcSEcCtD
Cyclobenzaprine—Alopecia—Methotrexate—breast cancer	2.16e-05	0.000306	CcSEcCtD
Cyclobenzaprine—Vomiting—Gemcitabine—breast cancer	2.16e-05	0.000306	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Docetaxel—breast cancer	2.15e-05	0.000305	CcSEcCtD
Cyclobenzaprine—Somnolence—Docetaxel—breast cancer	2.14e-05	0.000304	CcSEcCtD
Cyclobenzaprine—Rash—Gemcitabine—breast cancer	2.14e-05	0.000304	CcSEcCtD
Cyclobenzaprine—Dermatitis—Gemcitabine—breast cancer	2.14e-05	0.000303	CcSEcCtD
Cyclobenzaprine—Tinnitus—Epirubicin—breast cancer	2.13e-05	0.000303	CcSEcCtD
Cyclobenzaprine—Headache—Gemcitabine—breast cancer	2.12e-05	0.000302	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Capecitabine—breast cancer	2.12e-05	0.000302	CcSEcCtD
Cyclobenzaprine—Vomiting—Fluorouracil—breast cancer	2.12e-05	0.000301	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Docetaxel—breast cancer	2.12e-05	0.000301	CcSEcCtD
Cyclobenzaprine—Hepatitis—Doxorubicin—breast cancer	2.11e-05	0.0003	CcSEcCtD
Cyclobenzaprine—Insomnia—Capecitabine—breast cancer	2.11e-05	0.000299	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Doxorubicin—breast cancer	2.1e-05	0.000299	CcSEcCtD
Cyclobenzaprine—Rash—Fluorouracil—breast cancer	2.1e-05	0.000299	CcSEcCtD
Cyclobenzaprine—Dermatitis—Fluorouracil—breast cancer	2.1e-05	0.000298	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Doxorubicin—breast cancer	2.1e-05	0.000298	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Capecitabine—breast cancer	2.09e-05	0.000297	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Docetaxel—breast cancer	2.09e-05	0.000297	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Paclitaxel—breast cancer	2.09e-05	0.000297	CcSEcCtD
Cyclobenzaprine—Headache—Fluorouracil—breast cancer	2.09e-05	0.000297	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—breast cancer	2.08e-05	0.000296	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Capecitabine—breast cancer	2.08e-05	0.000295	CcSEcCtD
Cyclobenzaprine—Fatigue—Docetaxel—breast cancer	2.07e-05	0.000295	CcSEcCtD
Cyclobenzaprine—Carbamazepine—CYP3A4—breast cancer	2.07e-05	0.0134	CrCbGaD
Cyclobenzaprine—Nausea—Irinotecan—breast cancer	2.07e-05	0.000294	CcSEcCtD
Cyclobenzaprine—Nausea—Mitoxantrone—breast cancer	2.07e-05	0.000294	CcSEcCtD
Cyclobenzaprine—Constipation—Docetaxel—breast cancer	2.06e-05	0.000292	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Capecitabine—breast cancer	2.05e-05	0.000291	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Epirubicin—breast cancer	2.04e-05	0.00029	CcSEcCtD
Cyclobenzaprine—Asthenia—Paclitaxel—breast cancer	2.04e-05	0.000289	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Capecitabine—breast cancer	2.03e-05	0.000288	CcSEcCtD
Cyclobenzaprine—Alopecia—Epirubicin—breast cancer	2.02e-05	0.000287	CcSEcCtD
Cyclobenzaprine—Nausea—Gemcitabine—breast cancer	2.01e-05	0.000286	CcSEcCtD
Cyclobenzaprine—Fatigue—Capecitabine—breast cancer	2.01e-05	0.000285	CcSEcCtD
Cyclobenzaprine—Pruritus—Paclitaxel—breast cancer	2.01e-05	0.000285	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—breast cancer	2e-05	0.000285	CcSEcCtD
Cyclobenzaprine—Constipation—Capecitabine—breast cancer	1.99e-05	0.000283	CcSEcCtD
Cyclobenzaprine—Nortriptyline—CYP2D6—breast cancer	1.99e-05	0.0129	CrCbGaD
Cyclobenzaprine—Feeling abnormal—Docetaxel—breast cancer	1.98e-05	0.000282	CcSEcCtD
Cyclobenzaprine—Nausea—Fluorouracil—breast cancer	1.98e-05	0.000281	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—breast cancer	1.97e-05	0.00028	CcSEcCtD
Cyclobenzaprine—Tinnitus—Doxorubicin—breast cancer	1.97e-05	0.00028	CcSEcCtD
Cyclobenzaprine—Benzphetamine—CYP3A4—breast cancer	1.97e-05	0.0127	CrCbGaD
Cyclobenzaprine—Gastrointestinal pain—Docetaxel—breast cancer	1.97e-05	0.00028	CcSEcCtD
Cyclobenzaprine—Flatulence—Epirubicin—breast cancer	1.96e-05	0.000278	CcSEcCtD
Cyclobenzaprine—Tension—Epirubicin—breast cancer	1.95e-05	0.000277	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Epirubicin—breast cancer	1.95e-05	0.000277	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Paclitaxel—breast cancer	1.94e-05	0.000276	CcSEcCtD
Cyclobenzaprine—Nervousness—Epirubicin—breast cancer	1.93e-05	0.000274	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Capecitabine—breast cancer	1.92e-05	0.000273	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—breast cancer	1.92e-05	0.000272	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—breast cancer	1.91e-05	0.000271	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Capecitabine—breast cancer	1.91e-05	0.000271	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Docetaxel—breast cancer	1.9e-05	0.00027	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—breast cancer	1.9e-05	0.00027	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Doxorubicin—breast cancer	1.89e-05	0.000268	CcSEcCtD
Cyclobenzaprine—Dizziness—Paclitaxel—breast cancer	1.88e-05	0.000267	CcSEcCtD
Cyclobenzaprine—Vision blurred—Epirubicin—breast cancer	1.87e-05	0.000266	CcSEcCtD
Cyclobenzaprine—Trimipramine—CYP2D6—breast cancer	1.87e-05	0.0121	CrCbGaD
Cyclobenzaprine—Alopecia—Doxorubicin—breast cancer	1.87e-05	0.000265	CcSEcCtD
Cyclobenzaprine—Urticaria—Capecitabine—breast cancer	1.85e-05	0.000263	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Epirubicin—breast cancer	1.85e-05	0.000262	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Capecitabine—breast cancer	1.84e-05	0.000262	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—breast cancer	1.84e-05	0.000262	CcSEcCtD
Cyclobenzaprine—Diphenhydramine—CYP2D6—breast cancer	1.84e-05	0.0119	CrCbGaD
Cyclobenzaprine—Agitation—Epirubicin—breast cancer	1.83e-05	0.00026	CcSEcCtD
Cyclobenzaprine—Flatulence—Doxorubicin—breast cancer	1.81e-05	0.000258	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—breast cancer	1.81e-05	0.000257	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—breast cancer	1.81e-05	0.000257	CcSEcCtD
Cyclobenzaprine—Tension—Doxorubicin—breast cancer	1.81e-05	0.000257	CcSEcCtD
Cyclobenzaprine—Vomiting—Paclitaxel—breast cancer	1.81e-05	0.000256	CcSEcCtD
Cyclobenzaprine—Promethazine—CYP2D6—breast cancer	1.8e-05	0.0117	CrCbGaD
Cyclobenzaprine—Dysgeusia—Doxorubicin—breast cancer	1.8e-05	0.000256	CcSEcCtD
Cyclobenzaprine—Malaise—Epirubicin—breast cancer	1.79e-05	0.000255	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP2D6—breast cancer	1.79e-05	0.0116	CrCbGaD
Cyclobenzaprine—Rash—Paclitaxel—breast cancer	1.79e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Dermatitis—Paclitaxel—breast cancer	1.79e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—breast cancer	1.79e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Nervousness—Doxorubicin—breast cancer	1.79e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Vertigo—Epirubicin—breast cancer	1.79e-05	0.000254	CcSEcCtD
Cyclobenzaprine—Doxepin—CYP2D6—breast cancer	1.79e-05	0.0115	CrCbGaD
Cyclobenzaprine—Syncope—Epirubicin—breast cancer	1.78e-05	0.000253	CcSEcCtD
Cyclobenzaprine—Leukopenia—Epirubicin—breast cancer	1.78e-05	0.000253	CcSEcCtD
Cyclobenzaprine—Headache—Paclitaxel—breast cancer	1.78e-05	0.000253	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Docetaxel—breast cancer	1.77e-05	0.000252	CcSEcCtD
Cyclobenzaprine—Palpitations—Epirubicin—breast cancer	1.76e-05	0.00025	CcSEcCtD
Cyclobenzaprine—Confusional state—Methotrexate—breast cancer	1.75e-05	0.000248	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Epirubicin—breast cancer	1.75e-05	0.000248	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—breast cancer	1.73e-05	0.000246	CcSEcCtD
Cyclobenzaprine—Vision blurred—Doxorubicin—breast cancer	1.73e-05	0.000246	CcSEcCtD
Cyclobenzaprine—Asthenia—Docetaxel—breast cancer	1.73e-05	0.000245	CcSEcCtD
Cyclobenzaprine—Carbamazepine—ABCB1—breast cancer	1.73e-05	0.0112	CrCbGaD
Cyclobenzaprine—Convulsion—Epirubicin—breast cancer	1.72e-05	0.000245	CcSEcCtD
Cyclobenzaprine—Hypertension—Epirubicin—breast cancer	1.72e-05	0.000244	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Capecitabine—breast cancer	1.72e-05	0.000244	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Doxorubicin—breast cancer	1.71e-05	0.000243	CcSEcCtD
Cyclobenzaprine—Nortriptyline—CYP3A4—breast cancer	1.71e-05	0.011	CrCbGaD
Cyclobenzaprine—Pruritus—Docetaxel—breast cancer	1.7e-05	0.000242	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—breast cancer	1.7e-05	0.000241	CcSEcCtD
Cyclobenzaprine—Chest pain—Epirubicin—breast cancer	1.69e-05	0.000241	CcSEcCtD
Cyclobenzaprine—Myalgia—Epirubicin—breast cancer	1.69e-05	0.000241	CcSEcCtD
Cyclobenzaprine—Agitation—Doxorubicin—breast cancer	1.69e-05	0.00024	CcSEcCtD
Cyclobenzaprine—Anxiety—Epirubicin—breast cancer	1.69e-05	0.00024	CcSEcCtD
Cyclobenzaprine—Nausea—Paclitaxel—breast cancer	1.69e-05	0.00024	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—breast cancer	1.68e-05	0.000238	CcSEcCtD
Cyclobenzaprine—Discomfort—Epirubicin—breast cancer	1.67e-05	0.000238	CcSEcCtD
Cyclobenzaprine—Asthenia—Capecitabine—breast cancer	1.67e-05	0.000237	CcSEcCtD
Cyclobenzaprine—Malaise—Doxorubicin—breast cancer	1.66e-05	0.000236	CcSEcCtD
Cyclobenzaprine—Dry mouth—Epirubicin—breast cancer	1.66e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Vertigo—Doxorubicin—breast cancer	1.65e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—breast cancer	1.65e-05	0.000235	CcSEcCtD
Cyclobenzaprine—Syncope—Doxorubicin—breast cancer	1.65e-05	0.000234	CcSEcCtD
Cyclobenzaprine—Pruritus—Capecitabine—breast cancer	1.65e-05	0.000234	CcSEcCtD
Cyclobenzaprine—Leukopenia—Doxorubicin—breast cancer	1.65e-05	0.000234	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Docetaxel—breast cancer	1.65e-05	0.000234	CcSEcCtD
Cyclobenzaprine—Confusional state—Epirubicin—breast cancer	1.64e-05	0.000232	CcSEcCtD
Cyclobenzaprine—Palpitations—Doxorubicin—breast cancer	1.63e-05	0.000231	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Epirubicin—breast cancer	1.62e-05	0.000231	CcSEcCtD
Cyclobenzaprine—Oedema—Epirubicin—breast cancer	1.62e-05	0.000231	CcSEcCtD
Cyclobenzaprine—Hypotension—Methotrexate—breast cancer	1.62e-05	0.00023	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Doxorubicin—breast cancer	1.62e-05	0.00023	CcSEcCtD
Cyclobenzaprine—Trimipramine—CYP3A4—breast cancer	1.61e-05	0.0104	CrCbGaD
Cyclobenzaprine—Shock—Epirubicin—breast cancer	1.6e-05	0.000227	CcSEcCtD
Cyclobenzaprine—Convulsion—Doxorubicin—breast cancer	1.59e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Capecitabine—breast cancer	1.59e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Dizziness—Docetaxel—breast cancer	1.59e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Epirubicin—breast cancer	1.59e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Hypertension—Doxorubicin—breast cancer	1.59e-05	0.000226	CcSEcCtD
Cyclobenzaprine—Tachycardia—Epirubicin—breast cancer	1.58e-05	0.000225	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—breast cancer	1.58e-05	0.000224	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Epirubicin—breast cancer	1.57e-05	0.000223	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—breast cancer	1.57e-05	0.000223	CcSEcCtD
Cyclobenzaprine—Myalgia—Doxorubicin—breast cancer	1.57e-05	0.000223	CcSEcCtD
Cyclobenzaprine—Chest pain—Doxorubicin—breast cancer	1.57e-05	0.000223	CcSEcCtD
Cyclobenzaprine—Anxiety—Doxorubicin—breast cancer	1.56e-05	0.000222	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methotrexate—breast cancer	1.56e-05	0.000221	CcSEcCtD
Cyclobenzaprine—Discomfort—Doxorubicin—breast cancer	1.55e-05	0.00022	CcSEcCtD
Cyclobenzaprine—Anorexia—Epirubicin—breast cancer	1.55e-05	0.00022	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—breast cancer	1.55e-05	0.00022	CcSEcCtD
Cyclobenzaprine—Somnolence—Methotrexate—breast cancer	1.54e-05	0.000219	CcSEcCtD
Cyclobenzaprine—Dizziness—Capecitabine—breast cancer	1.54e-05	0.000219	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP3A4—breast cancer	1.54e-05	0.00994	CrCbGaD
Cyclobenzaprine—Dry mouth—Doxorubicin—breast cancer	1.53e-05	0.000218	CcSEcCtD
Cyclobenzaprine—Doxepin—CYP3A4—breast cancer	1.53e-05	0.0099	CrCbGaD
Cyclobenzaprine—Vomiting—Docetaxel—breast cancer	1.53e-05	0.000217	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methotrexate—breast cancer	1.53e-05	0.000217	CcSEcCtD
Cyclobenzaprine—Rash—Docetaxel—breast cancer	1.52e-05	0.000216	CcSEcCtD
Cyclobenzaprine—Hypotension—Epirubicin—breast cancer	1.52e-05	0.000215	CcSEcCtD
Cyclobenzaprine—Dermatitis—Docetaxel—breast cancer	1.52e-05	0.000215	CcSEcCtD
Cyclobenzaprine—Confusional state—Doxorubicin—breast cancer	1.51e-05	0.000215	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—breast cancer	1.51e-05	0.000214	CcSEcCtD
Cyclobenzaprine—Headache—Docetaxel—breast cancer	1.51e-05	0.000214	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Doxorubicin—breast cancer	1.5e-05	0.000213	CcSEcCtD
Cyclobenzaprine—Oedema—Doxorubicin—breast cancer	1.5e-05	0.000213	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—breast cancer	1.5e-05	0.000212	CcSEcCtD
Cyclobenzaprine—Orphenadrine—CYP3A4—breast cancer	1.49e-05	0.00965	CrCbGaD
Cyclobenzaprine—Nortriptyline—ALB—breast cancer	1.49e-05	0.00963	CrCbGaD
Cyclobenzaprine—Vomiting—Capecitabine—breast cancer	1.48e-05	0.00021	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Epirubicin—breast cancer	1.48e-05	0.00021	CcSEcCtD
Cyclobenzaprine—Shock—Doxorubicin—breast cancer	1.48e-05	0.00021	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Doxorubicin—breast cancer	1.47e-05	0.000209	CcSEcCtD
Cyclobenzaprine—Rash—Capecitabine—breast cancer	1.47e-05	0.000209	CcSEcCtD
Cyclobenzaprine—Insomnia—Epirubicin—breast cancer	1.47e-05	0.000209	CcSEcCtD
Cyclobenzaprine—Dermatitis—Capecitabine—breast cancer	1.47e-05	0.000208	CcSEcCtD
Cyclobenzaprine—Tachycardia—Doxorubicin—breast cancer	1.47e-05	0.000208	CcSEcCtD
Cyclobenzaprine—Headache—Capecitabine—breast cancer	1.46e-05	0.000207	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Epirubicin—breast cancer	1.46e-05	0.000207	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Doxorubicin—breast cancer	1.45e-05	0.000206	CcSEcCtD
Cyclobenzaprine—Chlorprothixene—ABCB1—breast cancer	1.45e-05	0.00936	CrCbGaD
Cyclobenzaprine—Dyspnoea—Epirubicin—breast cancer	1.45e-05	0.000206	CcSEcCtD
Cyclobenzaprine—Somnolence—Epirubicin—breast cancer	1.44e-05	0.000205	CcSEcCtD
Cyclobenzaprine—Anorexia—Doxorubicin—breast cancer	1.43e-05	0.000203	CcSEcCtD
Cyclobenzaprine—Nausea—Docetaxel—breast cancer	1.43e-05	0.000203	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methotrexate—breast cancer	1.43e-05	0.000203	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Epirubicin—breast cancer	1.43e-05	0.000203	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—breast cancer	1.42e-05	0.000201	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Epirubicin—breast cancer	1.41e-05	0.0002	CcSEcCtD
Cyclobenzaprine—Hypotension—Doxorubicin—breast cancer	1.4e-05	0.000199	CcSEcCtD
Cyclobenzaprine—Fatigue—Epirubicin—breast cancer	1.4e-05	0.000199	CcSEcCtD
Cyclobenzaprine—Imipramine—CYP2D6—breast cancer	1.39e-05	0.00899	CrCbGaD
Cyclobenzaprine—Constipation—Epirubicin—breast cancer	1.39e-05	0.000197	CcSEcCtD
Cyclobenzaprine—Nausea—Capecitabine—breast cancer	1.38e-05	0.000197	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP2D6—breast cancer	1.38e-05	0.00893	CrCbGaD
Cyclobenzaprine—Urticaria—Methotrexate—breast cancer	1.38e-05	0.000196	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methotrexate—breast cancer	1.37e-05	0.000195	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.37e-05	0.000194	CcSEcCtD
Cyclobenzaprine—Promazine—CYP3A4—breast cancer	1.36e-05	0.0088	CrCbGaD
Cyclobenzaprine—Insomnia—Doxorubicin—breast cancer	1.36e-05	0.000193	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Doxorubicin—breast cancer	1.35e-05	0.000192	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Doxorubicin—breast cancer	1.34e-05	0.00019	CcSEcCtD
Cyclobenzaprine—Trimipramine—ABCB1—breast cancer	1.34e-05	0.00865	CrCbGaD
Cyclobenzaprine—Feeling abnormal—Epirubicin—breast cancer	1.34e-05	0.00019	CcSEcCtD
Cyclobenzaprine—Somnolence—Doxorubicin—breast cancer	1.34e-05	0.00019	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Epirubicin—breast cancer	1.33e-05	0.000189	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Doxorubicin—breast cancer	1.32e-05	0.000188	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Doxorubicin—breast cancer	1.31e-05	0.000185	CcSEcCtD
Cyclobenzaprine—Fatigue—Doxorubicin—breast cancer	1.29e-05	0.000184	CcSEcCtD
Cyclobenzaprine—Urticaria—Epirubicin—breast cancer	1.29e-05	0.000183	CcSEcCtD
Cyclobenzaprine—Promethazine—ABCB1—breast cancer	1.29e-05	0.00833	CrCbGaD
Cyclobenzaprine—Constipation—Doxorubicin—breast cancer	1.28e-05	0.000182	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Epirubicin—breast cancer	1.28e-05	0.000182	CcSEcCtD
Cyclobenzaprine—Tamoxifen—ABCB1—breast cancer	1.28e-05	0.00827	CrCbGaD
Cyclobenzaprine—Hypersensitivity—Methotrexate—breast cancer	1.28e-05	0.000182	CcSEcCtD
Cyclobenzaprine—Doxepin—ABCB1—breast cancer	1.27e-05	0.00825	CrCbGaD
Cyclobenzaprine—Asthenia—Methotrexate—breast cancer	1.24e-05	0.000177	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Doxorubicin—breast cancer	1.24e-05	0.000176	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Doxorubicin—breast cancer	1.23e-05	0.000174	CcSEcCtD
Cyclobenzaprine—Pruritus—Methotrexate—breast cancer	1.23e-05	0.000174	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Epirubicin—breast cancer	1.2e-05	0.00017	CcSEcCtD
Cyclobenzaprine—Urticaria—Doxorubicin—breast cancer	1.19e-05	0.000169	CcSEcCtD
Cyclobenzaprine—Imipramine—CYP3A4—breast cancer	1.19e-05	0.00771	CrCbGaD
Cyclobenzaprine—Abdominal pain—Doxorubicin—breast cancer	1.19e-05	0.000169	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methotrexate—breast cancer	1.19e-05	0.000169	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP3A4—breast cancer	1.18e-05	0.00766	CrCbGaD
Cyclobenzaprine—Asthenia—Epirubicin—breast cancer	1.16e-05	0.000165	CcSEcCtD
Cyclobenzaprine—Pruritus—Epirubicin—breast cancer	1.15e-05	0.000163	CcSEcCtD
Cyclobenzaprine—Dizziness—Methotrexate—breast cancer	1.15e-05	0.000163	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Epirubicin—breast cancer	1.11e-05	0.000158	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Doxorubicin—breast cancer	1.11e-05	0.000157	CcSEcCtD
Cyclobenzaprine—Vomiting—Methotrexate—breast cancer	1.1e-05	0.000157	CcSEcCtD
Cyclobenzaprine—Rash—Methotrexate—breast cancer	1.09e-05	0.000155	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—breast cancer	1.09e-05	0.000155	CcSEcCtD
Cyclobenzaprine—Headache—Methotrexate—breast cancer	1.09e-05	0.000154	CcSEcCtD
Cyclobenzaprine—Asthenia—Doxorubicin—breast cancer	1.08e-05	0.000153	CcSEcCtD
Cyclobenzaprine—Dizziness—Epirubicin—breast cancer	1.07e-05	0.000152	CcSEcCtD
Cyclobenzaprine—Pruritus—Doxorubicin—breast cancer	1.06e-05	0.000151	CcSEcCtD
Cyclobenzaprine—Amitriptyline—ALB—breast cancer	1.03e-05	0.00668	CrCbGaD
Cyclobenzaprine—Vomiting—Epirubicin—breast cancer	1.03e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Nausea—Methotrexate—breast cancer	1.03e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Doxorubicin—breast cancer	1.03e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Rash—Epirubicin—breast cancer	1.02e-05	0.000145	CcSEcCtD
Cyclobenzaprine—Dermatitis—Epirubicin—breast cancer	1.02e-05	0.000145	CcSEcCtD
Cyclobenzaprine—Headache—Epirubicin—breast cancer	1.02e-05	0.000144	CcSEcCtD
Cyclobenzaprine—Dizziness—Doxorubicin—breast cancer	9.93e-06	0.000141	CcSEcCtD
Cyclobenzaprine—Imipramine—ABCB1—breast cancer	9.92e-06	0.00642	CrCbGaD
Cyclobenzaprine—Amitriptyline—ABCB1—breast cancer	9.86e-06	0.00638	CrCbGaD
Cyclobenzaprine—Nausea—Epirubicin—breast cancer	9.64e-06	0.000137	CcSEcCtD
Cyclobenzaprine—Vomiting—Doxorubicin—breast cancer	9.55e-06	0.000136	CcSEcCtD
Cyclobenzaprine—Rash—Doxorubicin—breast cancer	9.47e-06	0.000135	CcSEcCtD
Cyclobenzaprine—Dermatitis—Doxorubicin—breast cancer	9.46e-06	0.000134	CcSEcCtD
Cyclobenzaprine—Headache—Doxorubicin—breast cancer	9.41e-06	0.000134	CcSEcCtD
Cyclobenzaprine—Nausea—Doxorubicin—breast cancer	8.92e-06	0.000127	CcSEcCtD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGF10—breast cancer	3.02e-06	0.000152	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HBA1—breast cancer	3.01e-06	0.000152	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ACHE—breast cancer	2.94e-06	0.000148	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTT1—breast cancer	2.94e-06	0.000148	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CD—breast cancer	2.92e-06	0.000147	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDGFA—breast cancer	2.92e-06	0.000147	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HMMR—breast cancer	2.92e-06	0.000147	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA3—breast cancer	2.92e-06	0.000147	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCC1—breast cancer	2.92e-06	0.000147	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	2.91e-06	0.000147	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFBR2—breast cancer	2.88e-06	0.000145	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ITPR1—breast cancer	2.83e-06	0.000143	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PPARGC1B—breast cancer	2.83e-06	0.000142	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MED12—breast cancer	2.82e-06	0.000142	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—DPYD—breast cancer	2.82e-06	0.000142	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT5A—breast cancer	2.81e-06	0.000142	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB4—breast cancer	2.81e-06	0.000142	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MMP3—breast cancer	2.81e-06	0.000142	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CB—breast cancer	2.8e-06	0.000141	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP17A1—breast cancer	2.79e-06	0.00014	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALDOA—breast cancer	2.78e-06	0.00014	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ENO1—breast cancer	2.76e-06	0.000139	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTGS1—breast cancer	2.76e-06	0.000139	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SMAD4—breast cancer	2.72e-06	0.000137	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IGF1R—breast cancer	2.71e-06	0.000136	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—CXCL8—breast cancer	2.69e-06	0.000136	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA3—breast cancer	2.69e-06	0.000136	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC2A2—breast cancer	2.68e-06	0.000135	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CA9—breast cancer	2.67e-06	0.000135	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA4—breast cancer	2.67e-06	0.000135	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HES1—breast cancer	2.66e-06	0.000134	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOA2—breast cancer	2.65e-06	0.000134	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	2.65e-06	0.000133	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PLA2G4A—breast cancer	2.64e-06	0.000133	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NCOR1—breast cancer	2.64e-06	0.000133	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ABCG2—breast cancer	2.62e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CPT1A—breast cancer	2.62e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTR—breast cancer	2.62e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGF1—breast cancer	2.61e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CSF2—breast cancer	2.61e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—RAF1—breast cancer	2.61e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA2—breast cancer	2.6e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GPX2—breast cancer	2.6e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NRG1—breast cancer	2.6e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—H2AFX—breast cancer	2.58e-06	0.00013	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—IL2—breast cancer	2.58e-06	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—FASN—breast cancer	2.57e-06	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HPGDS—breast cancer	2.57e-06	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SULT1A1—breast cancer	2.57e-06	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GPX4—breast cancer	2.57e-06	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—BCHE—breast cancer	2.56e-06	0.000129	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—E2F1—breast cancer	2.56e-06	0.000129	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HBA1—breast cancer	2.55e-06	0.000129	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CB—breast cancer	2.55e-06	0.000128	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC5A5—breast cancer	2.53e-06	0.000128	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—IDH1—breast cancer	2.51e-06	0.000126	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA1—breast cancer	2.51e-06	0.000126	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTT1—breast cancer	2.49e-06	0.000126	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ACHE—breast cancer	2.49e-06	0.000126	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NAT2—breast cancer	2.48e-06	0.000125	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SPP1—breast cancer	2.46e-06	0.000124	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CXCL8—breast cancer	2.45e-06	0.000123	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NQO1—breast cancer	2.45e-06	0.000123	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC2A1—breast cancer	2.45e-06	0.000123	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB3—breast cancer	2.43e-06	0.000123	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGFR2—breast cancer	2.43e-06	0.000122	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP3A4—breast cancer	2.38e-06	0.00012	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP17A1—breast cancer	2.36e-06	0.000119	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP1B1—breast cancer	2.34e-06	0.000118	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL2—breast cancer	2.34e-06	0.000118	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTGS1—breast cancer	2.34e-06	0.000118	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ENO1—breast cancer	2.34e-06	0.000118	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TERT—breast cancer	2.33e-06	0.000117	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	2.33e-06	0.000117	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HSP90AA1—breast cancer	2.3e-06	0.000116	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	2.3e-06	0.000116	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2D6—breast cancer	2.29e-06	0.000115	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGFR1—breast cancer	2.26e-06	0.000114	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA2—breast cancer	2.25e-06	0.000113	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOA1—breast cancer	2.24e-06	0.000113	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HIF1A—breast cancer	2.23e-06	0.000112	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—STK11—breast cancer	2.2e-06	0.000111	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP19A1—breast cancer	2.2e-06	0.000111	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—FASN—breast cancer	2.18e-06	0.00011	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—DPYD—breast cancer	2.18e-06	0.00011	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MED12—breast cancer	2.18e-06	0.00011	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—LEP—breast cancer	2.18e-06	0.00011	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—BCHE—breast cancer	2.17e-06	0.000109	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CAV1—breast cancer	2.16e-06	0.000109	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC5A5—breast cancer	2.15e-06	0.000108	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALDOA—breast cancer	2.14e-06	0.000108	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KDR—breast cancer	2.13e-06	0.000107	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA3—breast cancer	2.08e-06	0.000105	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ESR1—breast cancer	2.08e-06	0.000105	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NQO1—breast cancer	2.07e-06	0.000104	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC2A1—breast cancer	2.07e-06	0.000104	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC2A2—breast cancer	2.06e-06	0.000104	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FN1—breast cancer	2.05e-06	0.000103	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—COMT—breast cancer	2.05e-06	0.000103	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTP1—breast cancer	2.04e-06	0.000103	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	2.03e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NFKBIA—breast cancer	2.03e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CPT1A—breast cancer	2.02e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCG2—breast cancer	2.02e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTR—breast cancer	2.02e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP3A4—breast cancer	2.02e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HMOX1—breast cancer	2.01e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	2.01e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOTCH1—breast cancer	2.01e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ITPR1—breast cancer	2.01e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP1B1—breast cancer	1.99e-06	0.0001	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HPGDS—breast cancer	1.98e-06	0.0001	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HBA1—breast cancer	1.97e-06	9.94e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KIT—breast cancer	1.96e-06	9.9e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CG—breast cancer	1.96e-06	9.9e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—APC—breast cancer	1.96e-06	9.9e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HSP90AA1—breast cancer	1.95e-06	9.82e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EGF—breast cancer	1.94e-06	9.78e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ABCB1—breast cancer	1.93e-06	9.73e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTT1—breast cancer	1.92e-06	9.7e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ACHE—breast cancer	1.92e-06	9.7e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TYMS—breast cancer	1.9e-06	9.56e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA1—breast cancer	1.89e-06	9.55e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—MAPK3—breast cancer	1.88e-06	9.48e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOR1—breast cancer	1.87e-06	9.45e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.87e-06	9.45e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTM1—breast cancer	1.87e-06	9.45e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—STK11—breast cancer	1.87e-06	9.41e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP19A1—breast cancer	1.87e-06	9.41e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—BRAF—breast cancer	1.85e-06	9.3e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP17A1—breast cancer	1.82e-06	9.18e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ENO1—breast cancer	1.8e-06	9.09e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTGS1—breast cancer	1.8e-06	9.09e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IGF1—breast cancer	1.8e-06	9.06e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—AKT2—breast cancer	1.8e-06	9.05e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GPX1—breast cancer	1.79e-06	9.05e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—EGFR—breast cancer	1.79e-06	9.02e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP1A1—breast cancer	1.78e-06	8.96e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2D6—breast cancer	1.77e-06	8.91e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ERCC2—breast cancer	1.76e-06	8.88e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.75e-06	8.84e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—COMT—breast cancer	1.74e-06	8.75e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA2—breast cancer	1.74e-06	8.75e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTP1—breast cancer	1.73e-06	8.71e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CD—breast cancer	1.73e-06	8.7e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	1.71e-06	8.62e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SERPINE1—breast cancer	1.71e-06	8.6e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HMOX1—breast cancer	1.7e-06	8.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ITPR1—breast cancer	1.7e-06	8.57e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—KRAS—breast cancer	1.69e-06	8.52e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—FASN—breast cancer	1.68e-06	8.48e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—BCHE—breast cancer	1.68e-06	8.45e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MTHFR—breast cancer	1.66e-06	8.35e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC5A5—breast cancer	1.66e-06	8.34e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ABCB1—breast cancer	1.64e-06	8.24e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOS3—breast cancer	1.63e-06	8.21e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TYMS—breast cancer	1.61e-06	8.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NQO1—breast cancer	1.6e-06	8.06e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC2A1—breast cancer	1.6e-06	8.06e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTM1—breast cancer	1.59e-06	8e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.59e-06	8e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOR1—breast cancer	1.59e-06	8e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	1.55e-06	7.82e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MDM2—breast cancer	1.55e-06	7.79e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RAF1—breast cancer	1.54e-06	7.77e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RELA—breast cancer	1.53e-06	7.73e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP1B1—breast cancer	1.53e-06	7.73e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CAV1—breast cancer	1.53e-06	7.7e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB2—breast cancer	1.52e-06	7.68e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GPX1—breast cancer	1.52e-06	7.66e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP1A1—breast cancer	1.51e-06	7.59e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MTOR—breast cancer	1.5e-06	7.58e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CB—breast cancer	1.5e-06	7.58e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.5e-06	7.58e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ERCC2—breast cancer	1.49e-06	7.53e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA1—breast cancer	1.46e-06	7.37e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CXCL8—breast cancer	1.45e-06	7.29e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—STK11—breast cancer	1.44e-06	7.26e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP19A1—breast cancer	1.44e-06	7.26e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—HRAS—breast cancer	1.44e-06	7.24e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1B—breast cancer	1.41e-06	7.12e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTHFR—breast cancer	1.4e-06	7.07e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—AKT1—breast cancer	1.4e-06	7.04e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CG—breast cancer	1.39e-06	7.02e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CASP3—breast cancer	1.38e-06	6.97e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL2—breast cancer	1.38e-06	6.96e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL6—breast cancer	1.37e-06	6.93e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCND1—breast cancer	1.35e-06	6.79e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JUN—breast cancer	1.34e-06	6.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—COMT—breast cancer	1.34e-06	6.75e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CTNNB1—breast cancer	1.33e-06	6.72e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTP1—breast cancer	1.33e-06	6.72e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HMOX1—breast cancer	1.32e-06	6.63e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ITPR1—breast cancer	1.31e-06	6.61e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MMP9—breast cancer	1.31e-06	6.59e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	1.3e-06	6.57e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTEN—breast cancer	1.3e-06	6.55e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CAV1—breast cancer	1.29e-06	6.52e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK8—breast cancer	1.27e-06	6.41e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—AKT1—breast cancer	1.27e-06	6.39e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCB1—breast cancer	1.26e-06	6.36e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TYMS—breast cancer	1.24e-06	6.25e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.24e-06	6.23e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.23e-06	6.18e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOR1—breast cancer	1.23e-06	6.18e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTM1—breast cancer	1.23e-06	6.18e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CD—breast cancer	1.22e-06	6.17e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALB—breast cancer	1.21e-06	6.09e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SRC—breast cancer	1.21e-06	6.08e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CG—breast cancer	1.18e-06	5.94e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—VEGFA—breast cancer	1.17e-06	5.92e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GPX1—breast cancer	1.17e-06	5.92e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT3—breast cancer	1.16e-06	5.86e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP1A1—breast cancer	1.16e-06	5.86e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NOS3—breast cancer	1.16e-06	5.82e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ERCC2—breast cancer	1.15e-06	5.81e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK3—breast cancer	1.11e-06	5.6e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTHFR—breast cancer	1.08e-06	5.46e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MYC—breast cancer	1.08e-06	5.44e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.08e-06	5.43e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CB—breast cancer	1.07e-06	5.38e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTGS2—breast cancer	1.06e-06	5.33e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EGFR—breast cancer	1.06e-06	5.33e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CD—breast cancer	1.04e-06	5.22e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALB—breast cancer	1.02e-06	5.16e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CAV1—breast cancer	9.99e-07	5.04e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KRAS—breast cancer	9.98e-07	5.03e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NOS3—breast cancer	9.79e-07	4.93e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTEN—breast cancer	9.22e-07	4.65e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	9.17e-07	4.62e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CG—breast cancer	9.1e-07	4.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CB—breast cancer	9.03e-07	4.55e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTGS2—breast cancer	8.95e-07	4.51e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TP53—breast cancer	8.87e-07	4.47e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HRAS—breast cancer	8.48e-07	4.28e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL6—breast cancer	8.12e-07	4.09e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CD—breast cancer	8e-07	4.03e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALB—breast cancer	7.9e-07	3.98e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTEN—breast cancer	7.81e-07	3.94e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NOS3—breast cancer	7.55e-07	3.81e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—AKT1—breast cancer	7.49e-07	3.78e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CB—breast cancer	6.97e-07	3.51e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTGS2—breast cancer	6.91e-07	3.48e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CA—breast cancer	6.5e-07	3.28e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTEN—breast cancer	6.03e-07	3.04e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CA—breast cancer	5.51e-07	2.78e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—AKT1—breast cancer	5.31e-07	2.68e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—AKT1—breast cancer	4.5e-07	2.27e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CA—breast cancer	4.25e-07	2.14e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—AKT1—breast cancer	3.47e-07	1.75e-05	CbGpPWpGaD
